TY - JOUR
T1 - Forging the path to precision medicine in Qatar
T2 - a public health perspective on pharmacogenomics initiatives
AU - Bastaki, Kholoud
AU - Velayutham, Dinesh
AU - Irfan, Areeba
AU - Adnan, Mohd
AU - Mohammed, Sawsan
AU - Mbarek, Hamdi
AU - Qoronfleh, M. Waild
AU - Jithesh, Puthen Veettil
N1 - Publisher Copyright:
Copyright © 2024 Bastaki, Velayutham, Irfan, Adnan, Mohammed, Mbarek, Qoronfleh and Jithesh.
PY - 2024
Y1 - 2024
N2 - Pharmacogenomics (PGx) is an important component of precision medicine that promises tailored treatment approaches based on an individual’s genetic information. Exploring the initiatives in research that help to integrate PGx test into clinical setting, identifying the potential barriers and challenges as well as planning the future directions, are all important for fruitful PGx implementation in any population. Qatar serves as an exemplar case study for the Middle East, having a small native population compared to a diverse immigrant population, advanced healthcare system, national genome program, and several educational initiatives on PGx and precision medicine. This paper attempts to outline the current state of PGx research and implementation in Qatar within the global context, emphasizing ongoing initiatives and educational efforts. The inclusion of PGx in university curricula and healthcare provider training, alongside precision medicine conferences, showcase Qatar’s commitment to advancing this field. However, challenges persist, including the requirement for population specific implementation strategies, complex genetic data interpretation, lack of standardization, and limited awareness. The review suggests policy development for future directions in continued research investment, conducting clinical trials for the feasibility of PGx implementation, ethical considerations, technological advancements, and global collaborations to overcome these barriers.
AB - Pharmacogenomics (PGx) is an important component of precision medicine that promises tailored treatment approaches based on an individual’s genetic information. Exploring the initiatives in research that help to integrate PGx test into clinical setting, identifying the potential barriers and challenges as well as planning the future directions, are all important for fruitful PGx implementation in any population. Qatar serves as an exemplar case study for the Middle East, having a small native population compared to a diverse immigrant population, advanced healthcare system, national genome program, and several educational initiatives on PGx and precision medicine. This paper attempts to outline the current state of PGx research and implementation in Qatar within the global context, emphasizing ongoing initiatives and educational efforts. The inclusion of PGx in university curricula and healthcare provider training, alongside precision medicine conferences, showcase Qatar’s commitment to advancing this field. However, challenges persist, including the requirement for population specific implementation strategies, complex genetic data interpretation, lack of standardization, and limited awareness. The review suggests policy development for future directions in continued research investment, conducting clinical trials for the feasibility of PGx implementation, ethical considerations, technological advancements, and global collaborations to overcome these barriers.
KW - Middle East
KW - Qatar
KW - pharmacogenomics (PGx)
KW - population health
KW - precision health
KW - precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85188944031&partnerID=8YFLogxK
U2 - 10.3389/fpubh.2024.1364221
DO - 10.3389/fpubh.2024.1364221
M3 - Review article
C2 - 38550311
AN - SCOPUS:85188944031
SN - 2296-2565
VL - 12
JO - Frontiers in Public Health
JF - Frontiers in Public Health
M1 - 1364221
ER -